BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15032090)

  • 1. [The autoimmune lymphoproliferative syndrome: a disorder of programmed cell death].
    Seegers D; Peña AS; Bouma G
    Ned Tijdschr Geneeskd; 2004 Feb; 148(8):371-6. PubMed ID: 15032090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autoimmune lymphoproliferative syndrome presenting with glomerulonephritis.
    Kanegane H; Vilela MM; Wang Y; Futatani T; Matsukura H; Miyawaki T
    Pediatr Nephrol; 2003 May; 18(5):454-6. PubMed ID: 12736807
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autoimmune lymphoproliferative syndrome with defective Fas: genotype influences penetrance.
    Jackson CE; Fischer RE; Hsu AP; Anderson SM; Choi Y; Wang J; Dale JK; Fleisher TA; Middelton LA; Sneller MC; Lenardo MJ; Straus SE; Puck JM
    Am J Hum Genet; 1999 Apr; 64(4):1002-14. PubMed ID: 10090885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome.
    Straus SE; Sneller M; Lenardo MJ; Puck JM; Strober W
    Ann Intern Med; 1999 Apr; 130(7):591-601. PubMed ID: 10189330
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALPS: an autoimmune human lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Puck JM; Sneller MC
    Semin Immunol; 1997 Feb; 9(1):77-84. PubMed ID: 9106310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of new Fas mutations in a patient with autoimmune lymphoproliferative syndrome (ALPS) and eosinophilia.
    Aspinall AI; Pinto A; Auer IA; Bridges P; Luider J; Dimnik L; Patel KD; Jorgenson K; Woodman RC
    Blood Cells Mol Dis; 1999; 25(3-4):227-38. PubMed ID: 10575548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autoimmune lymphoproliferative syndrome: molecular basis of disease and clinical phenotype.
    Worth A; Thrasher AJ; Gaspar HB
    Br J Haematol; 2006 Apr; 133(2):124-40. PubMed ID: 16611303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Residual CD95-pathway function in children with autoimmune lymphoproliferative syndrome is independent from clinical state and genotype of CD95 mutation.
    Fuchs H; Posovszky C; Lahr G; van der Werff ten Bosch J; Boehler T; Debatin KM
    Pediatr Res; 2009 Feb; 65(2):163-8. PubMed ID: 18948840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autoimmune lymphoproliferative syndrome (ALPS) in a patient with a new germline Fas gene mutation.
    Del-Rey MJ; Manzanares J; Bosque A; Aguiló JI; Gómez-Rial J; Roldan E; Serrano A; Anel A; Paz-Artal E; Allende LM
    Immunobiology; 2007; 212(2):73-83. PubMed ID: 17336828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clincal, immunologic, and genetic features of an autoimmune lymphoproliferative syndrome associated with abnormal lymphocyte apoptosis.
    Sneller MC; Wang J; Dale JK; Strober W; Middelton LA; Choi Y; Fleisher TA; Lim MS; Jaffe ES; Puck JM; Lenardo MJ; Straus SE
    Blood; 1997 Feb; 89(4):1341-8. PubMed ID: 9028957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human autoimmune lymphoproliferative syndrome, a defect in the apoptosis-inducing Fas receptor: a lesson from the mouse model.
    Nagata S
    J Hum Genet; 1998; 43(1):2-8. PubMed ID: 9609991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression in transgenic mice of dominant interfering Fas mutations: a model for human autoimmune lymphoproliferative syndrome.
    Choi Y; Ramnath VR; Eaton AS; Chen A; Simon-Stoos KL; Kleiner DE; Erikson J; Puck JM
    Clin Immunol; 1999 Oct; 93(1):34-45. PubMed ID: 10497009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HLA B44 is associated with decreased severity of autoimmune lymphoproliferative syndrome in patients with CD95 defects (ALPS type Ia).
    Vacek MM; Schäffer AA; Davis J; Fischer RE; Dale JK; Adams S; Straus SE; Puck JM
    Clin Immunol; 2006 Jan; 118(1):59-65. PubMed ID: 16257267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autoimmune lymphoproliferative syndrome.
    Sneller MC; Dale JK; Straus SE
    Curr Opin Rheumatol; 2003 Jul; 15(4):417-21. PubMed ID: 12819469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new disorder of lymphocyte apoptosis: combination of autoimmunity, infectious lymphadenopathy, double negative T cells, and impaired activation-induced cell death.
    Hundt M; Posovszky C; Schmidt RE
    Immunobiology; 2002 Dec; 206(5):514-8. PubMed ID: 12607726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The autoimmune lymphoproliferative syndrome: an experiment of nature involving lymphocyte apoptosis.
    Fleisher TA
    Immunol Res; 2008; 40(1):87-92. PubMed ID: 18193364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mycophenolate mofetil as an alternate immunosuppressor for autoimmune lymphoproliferative syndrome.
    Kossiva L; Theodoridou M; Mostrou G; Vrachnou E; Le Deist F; Rieux-Laucat F; Kanariou MG
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):824-6. PubMed ID: 17164652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome.
    Fisher GH; Rosenberg FJ; Straus SE; Dale JK; Middleton LA; Lin AY; Strober W; Lenardo MJ; Puck JM
    Cell; 1995 Jun; 81(6):935-46. PubMed ID: 7540117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autoimmune lymphoproliferative syndrome with somatic Fas mutations.
    Holzelova E; Vonarbourg C; Stolzenberg MC; Arkwright PD; Selz F; Prieur AM; Blanche S; Bartunkova J; Vilmer E; Fischer A; Le Deist F; Rieux-Laucat F
    N Engl J Med; 2004 Sep; 351(14):1409-18. PubMed ID: 15459302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Autoimmune lymphoproliferative syndrome, a disorder of apoptosis.
    Jackson CE; Puck JM
    Curr Opin Pediatr; 1999 Dec; 11(6):521-7. PubMed ID: 10590910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.